Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...
Le Lézard7h
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
USA News Group News Commentary ? The American Cancer Society recently released its Advances in Oncology ? 2024 Research Highlights report that highlighted how their scientists continued to set the ...
Silexion Therapeutics, Evonik collaborate on siRNA formulation development
Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA ...
Business Insider15h
Biotech Alert: Searches spiking for these stocks today
December 16 Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics to $7 from $4 and kept a Buy rating on the shares after the company announced FDA approval of ...